[go: up one dir, main page]

BR112012009289A2 - isolamento e purificação de anticorpos anti-il-13 com uso de cromatografia de afinidade com proteína a. - Google Patents

isolamento e purificação de anticorpos anti-il-13 com uso de cromatografia de afinidade com proteína a.

Info

Publication number
BR112012009289A2
BR112012009289A2 BR112012009289A BR112012009289A BR112012009289A2 BR 112012009289 A2 BR112012009289 A2 BR 112012009289A2 BR 112012009289 A BR112012009289 A BR 112012009289A BR 112012009289 A BR112012009289 A BR 112012009289A BR 112012009289 A2 BR112012009289 A2 BR 112012009289A2
Authority
BR
Brazil
Prior art keywords
antibodies
isolation
purification
affinity chromatography
protein affinity
Prior art date
Application number
BR112012009289A
Other languages
English (en)
Other versions
BR112012009289B8 (pt
BR112012009289A8 (pt
BR112012009289B1 (pt
Inventor
K Hickman Robert
Original Assignee
Abbott Laboratoires
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratoires filed Critical Abbott Laboratoires
Publication of BR112012009289A2 publication Critical patent/BR112012009289A2/pt
Publication of BR112012009289A8 publication Critical patent/BR112012009289A8/pt
Publication of BR112012009289B1 publication Critical patent/BR112012009289B1/pt
Publication of BR112012009289B8 publication Critical patent/BR112012009289B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A61K39/39525—Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

isolamento e purificação de anticorpos anti-il-13 com o uso de cromatografia de afinidade com proteína a. trata-se de métodos para o isolamento e purificação de anticorpos anti -il-13, em que o uso de uma etapa cromatográfica de afinidade resulta em uma composição de anti-corpo suficientemente pura para usos farmacêuticos. os métodos descritos no presente documento compreendem redução/inativação viral de ph, utrafiltração/diafiltração, cromatografia de afinidade (por exemplo, cromatografia de afinidade de proteína a), cromatografia de troca iônica, e cromatografia hidrofóbica. adicionalmente, a presente invenção está direcionada a composições farmacêuticas que compreendem um ou mais anticorpos da presente invenção.
BR112012009289A 2009-10-20 2010-10-20 método para purificar um anticorpo anti-il-13 a partir de uma mistura de amostra que compreende um anticorpo anti-il-13 e pelo menos uma proteína de célula hospedeira (hcp) BR112012009289B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25341109P 2009-10-20 2009-10-20
US61/253.411 2009-10-20
PCT/US2010/053388 WO2011050071A2 (en) 2009-10-20 2010-10-20 Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography

Publications (4)

Publication Number Publication Date
BR112012009289A2 true BR112012009289A2 (pt) 2017-04-04
BR112012009289A8 BR112012009289A8 (pt) 2017-12-05
BR112012009289B1 BR112012009289B1 (pt) 2021-01-05
BR112012009289B8 BR112012009289B8 (pt) 2021-05-25

Family

ID=43900936

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012009289A BR112012009289B8 (pt) 2009-10-20 2010-10-20 método para purificar um anticorpo anti-il-13 a partir de uma mistura de amostra que compreende um anticorpo anti-il-13 e pelo menos uma proteína de célula hospedeira (hcp)

Country Status (28)

Country Link
US (5) US8491904B2 (pt)
EP (2) EP2491055A2 (pt)
JP (1) JP5914342B2 (pt)
KR (2) KR101830596B1 (pt)
CN (2) CN102711828B (pt)
AU (1) AU2010310748C1 (pt)
BR (1) BR112012009289B8 (pt)
CA (1) CA2775595A1 (pt)
CY (1) CY1123952T1 (pt)
DK (1) DK3037104T3 (pt)
ES (1) ES2813398T3 (pt)
HR (1) HRP20201118T1 (pt)
HU (1) HUE053489T2 (pt)
IL (1) IL218897A (pt)
IN (1) IN2012DN02778A (pt)
LT (1) LT3037104T (pt)
MX (2) MX2012004711A (pt)
NZ (2) NZ627668A (pt)
PL (1) PL3037104T3 (pt)
PT (1) PT3037104T (pt)
RS (1) RS60577B1 (pt)
RU (1) RU2603055C2 (pt)
SG (1) SG10201406713XA (pt)
SI (1) SI3037104T1 (pt)
SM (1) SMT202000470T1 (pt)
TW (1) TWI515202B (pt)
WO (1) WO2011050071A2 (pt)
ZA (1) ZA201202720B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009068649A2 (en) * 2007-11-30 2009-06-04 Glaxo Group Limited Antigen-binding constructs
RU2551237C2 (ru) 2008-10-20 2015-05-20 Эббви Инк Инактивация вируса при очистке антител
RU2520838C2 (ru) * 2008-10-20 2014-06-27 Эббви Инк Выделение и очистка антител с использованием аффинной хроматографии на основе белка а
RS60577B1 (sr) 2009-10-20 2020-08-31 Abbvie Inc Izolacija i prečišćavanje anti-il-13 antitela upotrebom protein a afinitetne hromatografije
KR101627597B1 (ko) 2010-07-30 2016-06-08 이엠디 밀리포어 코포레이션 부직포 층
TWI700093B (zh) 2011-03-16 2020-08-01 法商賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
US20150038362A1 (en) * 2012-02-27 2015-02-05 Biogen Idec Ma Inc. High-Throughput Method For Sialic Acid Quantitation
JP6592426B2 (ja) 2013-03-15 2019-10-16 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 無塩条件下で疎水性相互作用クロマトグラフィーを使用するタンパク質精製
AU2014265624B2 (en) * 2013-05-15 2019-09-12 Medimmune Limited Purification of recombinantly produced polypeptides
TWI596107B (zh) 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
SG11201508835YA (en) 2013-07-12 2015-11-27 Merck Patent Gmbh Removal of fragments from a sample containing a target protein using activated carbon
EP4331605A3 (en) * 2013-09-13 2024-05-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
JP6546178B2 (ja) 2013-09-13 2019-07-17 ジェネンテック， インコーポレイテッド 細胞株中の宿主細胞タンパク質及び組換えポリペプチド産物を検出及び定量化するための組成物並びに方法
JPWO2015041218A1 (ja) * 2013-09-17 2017-03-02 株式会社カネカ 新規抗体精製方法及びそれから得られる抗体（ＮｏｖｅｌＡｎｔｉｂｏｄｙＰｕｒｉｆｉｃａｔｉｏｎＭｅｔｈｏｄａｎｄＡｎｔｉｂｏｄｙｏｂｔａｉｎｅｄｔｈｅｒｅｆｒｏｍ）、並びに陽イオン交換基を用いた新規抗体精製法及びそれから得られる抗体（ＮｏｖｅｌＡｎｔｉｂｏｄｙＰｕｒｉｆｉｃａｔｉｏｎｍｅｔｈｏｄｕｓｉｎｇＣａｔｉｏｎＥｘｃｈａｎｇｅｒａｎｄＡｎｔｉｂｏｄｙｏｂｔａｉｎｅｄｔｈｅｒｅｆｒｏｍ）
CN105017418B (zh) * 2014-03-27 2021-02-23 上海药明康德新药开发有限公司 单克隆抗体纯化工艺方法
FR3025515B1 (fr) * 2014-09-05 2016-09-09 Lab Francais Du Fractionnement Procede de purification d'un anticorps monoclonal
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
SG11201703399QA (en) 2014-12-08 2017-05-30 Emd Millipore Corp Mixed bed ion exchange adsorber
ES2995985T3 (en) 2015-08-13 2025-02-11 Amgen Inc Charged depth filtration of antigen-binding proteins
HK1259368A1 (zh) * 2015-08-20 2019-11-29 F. Hoffmann-La Roche Ag Fkpa的纯化及其用於生产重组多肽的用途
CN114617962A (zh) 2016-04-27 2022-06-14 艾伯维公司 使用抗-il-13抗体治疗il-13活性在其中有害的疾病的方法
IL309453A (en) 2016-08-16 2024-02-01 Regeneron Pharma A method for quantifying individual antibodies from a mixture
IL289895B (en) 2016-10-25 2022-09-01 Regeneron Pharma Methods and systems for analysis of chromatography data
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018140887A1 (en) * 2017-01-30 2018-08-02 Regeneron Pharmaceuticals, Inc. Method for reducing bioburden in chromatography
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
TWI679209B (zh) * 2017-04-14 2019-12-11 南韓商Ｃｊ醫藥健康股份有限公司 使用陽離子交換層析法純化同功抗體之方法
JP7097433B2 (ja) * 2017-08-17 2022-07-07 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 宿主細胞ガレクチンおよび他の夾雑物からグリコシル化タンパク質を精製する方法
CA3073935A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals, Inc. Methods of reducing particle formation and compositions formed thereby
TW202448568A (zh) 2018-07-02 2024-12-16 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
SG11202100653YA (en) * 2018-07-25 2021-02-25 Daiichi Sankyo Co Ltd Effective method for manufacturing antibody-drug conjugate
US12358999B2 (en) 2018-07-27 2025-07-15 Daiichi Sankyo Company, Limited Protein recognizing drug moiety of antibody-drug conjugate
CN110818789B (zh) * 2018-08-07 2023-02-28 三生国健药业（上海）股份有限公司 一种高纯度食蟹猴白细胞介素17a的纯化方法
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
TWI871300B (zh) * 2019-01-28 2025-02-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
AR119097A1 (es) * 2019-06-05 2021-11-24 Seattle Genetics Inc Métodos de purificación de anticuerpos enmascarados
US20220259261A1 (en) * 2019-08-01 2022-08-18 Regeneron Pharmaceuticals, Inc. Method for viral inactivation
TW202128745A (zh) 2019-12-06 2021-08-01 美商再生元醫藥公司 抗ｖｅｇｆ蛋白組合物及其製備方法
EP4309722A3 (en) 2019-12-13 2024-08-07 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
MY210396A (en) 2020-01-17 2025-09-18 Regeneron Pharma Hydrophobic interaction chromatography for viral clearance
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
CN112326966A (zh) * 2020-11-02 2021-02-05 杭州昱鼎生物科技有限公司 一种新型冠状病毒抗原的快速检测试剂盒及其制备方法和应用
WO2025029614A1 (en) * 2023-07-28 2025-02-06 Amgen Inc. A method for equilibrating a chromatography medium
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE266710C (pt)
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4534972A (en) 1983-03-29 1985-08-13 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE4041205A1 (de) 1990-12-21 1992-06-25 Schloemann Siemag Ag Verfahren und anlage zum auswalzen von warmbreitband aus stranggegossenen duennbrammen
DK1279731T3 (da) 1991-03-01 2007-09-24 Dyax Corp Fremgangsmåde til udvikling af bindende miniproteiner
ATE269401T1 (de) 1991-04-10 2004-07-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5457178A (en) * 1993-07-07 1995-10-10 Fmc Corporation Insecticidally effective spider toxin
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
EP0871436A4 (en) * 1995-06-30 1999-10-20 Smithkline Beecham Corp USE OF STAT 6 SH2 DOMAINE-SPECIFIC COMPOUNDS FOR TREATING ALLERGIC REACTIONS
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6955917B2 (en) * 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
EP1970448A1 (en) 2001-05-11 2008-09-17 Kirin Pharma Kabushiki Kaisha Human artificial chromosome containting human antibody lambda light chain and non-human animal containting the human artificial chromosome capable of genetic transmission
US7646782B1 (en) 2001-07-30 2010-01-12 Primrose Donald R Data link/physical layer packet buffering and flushing
CA2499269A1 (en) * 2002-09-17 2004-04-01 Gtc Biotherapeutics, Inc. Isolation of immunoglobulin molecules that lack inter-heavy chain disulfide bonds
PT1601697E (pt) * 2003-02-28 2007-09-04 Lonza Biologics Plc Purificação de anticorpos através de proteína a e cromatografia de troca iónica.
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
EP1678208B1 (en) 2003-10-27 2013-05-15 Wyeth LLC Removal of high molecular weight aggregates using hydroxyapatite chromatography
DE102004027816A1 (de) * 2004-06-08 2006-01-05 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von Erythropoietin
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
PL1942939T5 (pl) 2005-09-30 2021-10-11 Medimmune Limited Kompozycja przeciwciała interleukiny-13
GB0600488D0 (en) * 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
SG170837A1 (en) * 2006-04-05 2011-05-30 Abbott Biotech Ltd Antibody purification
BRPI0710820A2 (pt) * 2006-04-20 2011-08-23 Wyeth Corp processo para a purificação do vìrus da estomatite vesicular (vsv) do fluido de cultura celular de uma cultura de células de mamìferos infectada com vsv; vsv purificado de acordo com o processo; composição farmacêutica; e composição imunogênica
WO2009017491A1 (en) * 2006-06-14 2009-02-05 Smithkline Beecham Corporation Methods for purifying antibodies using ceramic hydroxyapatite
CN101512008B (zh) * 2006-09-08 2015-04-01 艾伯维巴哈马有限公司 白介素-13结合蛋白
RU2551237C2 (ru) * 2008-10-20 2015-05-20 Эббви Инк Инактивация вируса при очистке антител
JP2010209068A (ja) * 2009-03-11 2010-09-24 Wyeth Llc 小モジュラー免疫薬タンパク質を精製する方法
RS60577B1 (sr) 2009-10-20 2020-08-31 Abbvie Inc Izolacija i prečišćavanje anti-il-13 antitela upotrebom protein a afinitetne hromatografije

Also Published As

Publication number Publication date
MX341136B (es) 2016-08-09
IL218897A0 (en) 2012-06-28
CN102711828B (zh) 2015-06-17
IL218897A (en) 2016-03-31
BR112012009289B8 (pt) 2021-05-25
BR112012009289A8 (pt) 2017-12-05
JP5914342B2 (ja) 2016-05-11
AU2010310748B2 (en) 2015-05-21
RS60577B1 (sr) 2020-08-31
CN102711828A (zh) 2012-10-03
WO2011050071A2 (en) 2011-04-28
KR101830596B1 (ko) 2018-02-22
SMT202000470T1 (it) 2020-11-10
NZ599100A (en) 2014-07-25
HUE053489T2 (hu) 2021-06-28
CN104744560A (zh) 2015-07-01
US20180230210A1 (en) 2018-08-16
BR112012009289B1 (pt) 2021-01-05
KR20120101002A (ko) 2012-09-12
US20110206687A1 (en) 2011-08-25
CA2775595A1 (en) 2011-04-28
TW201125876A (en) 2011-08-01
SI3037104T1 (sl) 2020-10-30
AU2010310748C1 (en) 2015-11-26
KR20170136649A (ko) 2017-12-11
US9975948B2 (en) 2018-05-22
JP2013508387A (ja) 2013-03-07
EP2491055A2 (en) 2012-08-29
AU2010310748A1 (en) 2012-04-19
CY1123952T1 (el) 2022-03-24
PT3037104T (pt) 2020-07-07
US20160130339A1 (en) 2016-05-12
LT3037104T (lt) 2020-09-10
IN2012DN02778A (pt) 2015-09-18
PL3037104T3 (pl) 2020-11-16
HRP20201118T1 (hr) 2020-10-30
US11390668B2 (en) 2022-07-19
EP3037104B1 (en) 2020-05-27
US20130287771A1 (en) 2013-10-31
ZA201202720B (en) 2012-12-27
MX2012004711A (es) 2012-05-23
TWI515202B (zh) 2016-01-01
WO2011050071A3 (en) 2011-09-15
EP3037104A1 (en) 2016-06-29
US20220340656A1 (en) 2022-10-27
RU2012120751A (ru) 2013-11-27
US9266950B2 (en) 2016-02-23
SG10201406713XA (en) 2014-11-27
NZ627668A (en) 2016-03-31
DK3037104T3 (da) 2020-07-20
US12157767B2 (en) 2024-12-03
RU2603055C2 (ru) 2016-11-20
ES2813398T3 (es) 2021-03-23
US8491904B2 (en) 2013-07-23

Similar Documents

Publication Publication Date Title
BR112012009289A2 (pt) isolamento e purificação de anticorpos anti-il-13 com uso de cromatografia de afinidade com proteína a.
MX2018014395A (es) Aislamiento y purificacion de anticuerpos usando la cromatografia de afinidad de proteina a.
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
BR112015019066A2 (pt) Anticorpos humanos para proteína f do vírus respiratório sincicial e métodos de uso dos mesmos
GT201200271A (es) Proteínas que se unen al tnf-a
CO6612194A2 (es) Métodos de purificaciñon de adamts 13 y otras proteinas recombinantes y sus composiciones
BR112014020826A8 (pt) Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco – anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
BRPI0920572A8 (pt) Inativação viral durante a purificação dos anticorpos
BRPI0905733B8 (pt) composição, formulação farmacêutica, método para a produção de uma composição farmacêutica e uso de uma formulação farmacêutica
BR112013007314A2 (pt) anticorpos anti-cd48 e seus usos
BRPI0715396B8 (pt) método de produção de uma composição para vacina
CR10561A (es) Vacunas para malaria
BR112012004697A2 (pt) purificação melhorada de proteína através de uma eluição da proteína a modificada.
BR112015019879A2 (pt) Composições de espécies de variantes moduladas de lisina e métodos para produção e uso das mesmas
BRPI0919236A8 (pt) Terapêutica e vacinas de combinação de gas
BRPI0511616A (pt) compostos
CR11731A (es) Composiciones y procedimientos para su preparación y uso
BR112012004823A8 (pt) Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
BR112015014751A8 (pt) anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos.
ECSP099332A (es) Moléculas de enlace de lingo y uso farmacéutico de las mismas
BRPI1014544B8 (pt) anticorpo anti-il-17f monoclonal totalmente humano isolado e composição farmacêutica compreendendo o mesmo
CO6640289A2 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
BR112012022258A2 (pt) anticorpos monoclonais otimizados contra inibidor de trajetória de fator de tecido ( tfpi)

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ABBVIE INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/10/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF